Axial

Share this post
Axial - Cipher #4 (antibodies)
axial.substack.com

Axial - Cipher #4 (antibodies)

Finding the other half

Joshua Elkington
Aug 8, 2019
Comment
Share

Analysis of public clinical and business development data in life sciences.

Antibodies are the most reliably lucrative modality in life sciences right now. With Genentech pioneering the field and Adimab the business model. With the current pipeline full:

Active partnership activity:

With the average antibody deal value being over $1B now:

With the deals focused on oncology:

And research and license agreements:

Focused on discovery and phase I work due to the modality’s increased predictability in humans:

With deals having no geographic preference:

Thank you.

CommentComment
ShareShare

Create your profile

0 subscriptions will be displayed on your profile (edit)

Skip for now

Only paid subscribers can comment on this post

Already a paid subscriber? Sign in

Check your email

For your security, we need to re-authenticate you.

Click the link we sent to , or click here to sign in.

TopNewCommunity

No posts

Ready for more?

© 2022 Axial
Privacy ∙ Terms ∙ Collection notice
Publish on Substack Get the app
Substack is the home for great writing